Preferred Name |
axitinib |
|
Synonyms |
AG 013736 |
|
Definitions |
An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C38718" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38718" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000352181 |
|
altLabel |
AG 013736 Inlyta AG-013736 |
|
Component of | ||
cui |
C1328149 C3265883 C1700874 |
|
DATE FIRST PUBLISHED |
2004-01-23 |
|
Date last modified |
2012-01-27 |
|
definition |
An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C38718" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38718" NCI Thesaurus) |
|
LT |
TRD |
|
NCI ID |
C38718 |
|
notation |
CDR0000352181 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
axitinib |
|
tui |
T109 T121 |